Cend Therapeutics’ ongoing and planned clinical development programs are focused on a variety of cancers, including pancreatic and gastric cancer, as well as other types of hard-to-treat solid tumors. Concurrently, Cend Therapeutics works with investigators at leading medical institutions to extend our clinical development efforts through investigator-sponsored trials (ISTs).
CEND-1 + gemcitabine + nabpaclitaxel for Metastatic Pancreatic Cancer
Study CEND1-001 is a Phase 1 trial to evaluate the safety and preliminary of CEND-1 in combination with gemcitabine and nabpaclitaxel, a common standard-of-care therapy for pancreatic cancer. Adult subjects diagnosed with histologically confirmed metastatic pancreatic ductal carcinoma who have not received prior chemotherapy or any other investigational agents for the cancer treatment may be eligible.
learn more about CEND1-001 at https://www.clinicaltrials.gov
Expanded Access/Compassionate Use:
At this time, Cend Therapeutics does not offer expanded access or compassionate use programs for investigational agents under development. We evaluate the need on a continuous basis.